{"schema_version":"secwatch.filing_event.v1","accession":"0001828185-24-000063","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2024-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.461625+00:00","generated_at":"2026-06-01T05:59:58.781971+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Barinthus Bio VTP-300 data: 76% eligible to stop NUC therapy; significant HBsAg reduction vs placebo","bullets":["HBV003 (Phase 2b): 76% (16/21) eligible for NUC discontinuation; 19% achieved undetectable HBsAg.","IM-PROVE II (Phase 2a): statistically significant HBsAg reduction at 24 weeks post-EOT (p<0.05) vs placebo.","84% of VTP-300 group (16/19) met criteria to discontinue NUC therapy at EOT vs 52% placebo.","All treatment groups well-tolerated; no SAEs or Grade 3/4 treatment-related AEs in either trial.","Data cutoffs: April 15, 2024 (HBV003) and April 12, 2024 (IM-PROVE II); presented at EASL Congress 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001828185-24-000063","json":"https://secwatch.observer/filing/0001828185-24-000063.json","markdown":"https://secwatch.observer/filing/0001828185-24-000063.md","text":"https://secwatch.observer/filing/0001828185-24-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000063/0001828185-24-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000063/brns-20240606.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:59:58.781971+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}